Altre lingue TRACON Pharmaceuticals, Inc.

Azioni

TCON

US89237H3084

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
1,81 ^USD	+1,12%		-7,65%	-48,32%

03/04	TRACON Pharmaceuticals fornisce un aggiornamento sulla sperimentazione pivotale ENVASARC di Fase 2 in corso, in seguito alla raccomandazione del Comitato Indipendente di Monitoraggio dei Dati di continuare la sperimentazione come previsto.	CI
06/03	TRACON PHARMACEUTICALS, INC. : HC Wainwright ancora positivo	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

TRACON Pharmaceuticals Announces Reverse Stock Split	08/04
TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned	03/04
TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned	03/04
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05/03
Tracon: Q4 Earnings Snapshot	05/03
Earnings Flash (TCON) TRACON PHARMACEUTICALS Reports Q4 Revenue $3M, vs. Street Est of $1.5M	05/03
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update	05/03
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	05/03
TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024	28/02
TRACON Pharmaceuticals Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial	20/12
TRACON Pharmaceuticals, Inc. Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial	20/12
Tracon Licenses Product Development Platform for $3 Million Upfront Payment; Shares Jump	20/11
TRACON Pharmaceuticals, Inc. Announces License of Product Development Platform for $3.0 Million Upfront Payment	20/11
TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment	20/11
Wall Street Set to Open Slightly Higher as Investors Parse Powell Remarks	10/11
Exchange-Traded Funds, Equity Futures Rise After Fed Chief's Comments	10/11
Investors Parse Powell Remarks as US Futures Advance Slightly in Friday Trading	10/11
Top Premarket Gainers	10/11
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Tracon: Q3 Earnings Snapshot	09/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue TRACON Pharmaceuticals, Inc.

Azioni

TCON

US89237H3084

Altre lingue

Filtri